You are here

Point of Injury Therapy to Maintain and Stabilize Moderate-Severe Traumatic Brain Injury (TBI) Casualties.

Award Information
Agency: Department of Defense
Branch: Defense Health Agency
Contract: W81XWH-17-C-0222
Agency Tracking Number: H171-011-0072
Amount: $146,079.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: DHA17-011
Solicitation Number: 2017.1
Timeline
Solicitation Year: 2017
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-09-25
Award End Date (Contract End Date): 2018-04-24
Small Business Information
440 Burroughs Street
Detroit, MI 48202
United States
DUNS: 079716073
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: Yes
Principal Investigator
 John Anagli
 Chief Science Officer
 (248) 318-6521
 janagli@neurotheranostics.com
Business Contact
 John Anagli
Phone: (248) 318-6521
Email: janagli@neurotheranostics.com
Research Institution
N/A
Abstract

The objective of this particular proposal is to characterize the stability, brain availability, and pharmacokinetic/pharmacodynamic profiles of an intranasally administered selective calpain inhibitor-based therapeutic for moderate to severe TBI . The projects central hypothesis is that TBI causes overexpression and hyperactivation of calpain-1/2 that contribute to traumatic axonal injury and blood-brain barrier (BBB) compromise via multiple molecular and/or cellular pathways. Thus, selective pharmacological inhibition of the target protease would result in brain tissue protection and improvement of functional outcome. We have formulated this hypothesis based on available published data and preliminary findings from our laboratory which collectively support the idea that selective inhibition of calpain-1/2 may not only have neuroprotective effect but also enhance neuronal plasticity and repair and in this way improve functional outcome after TBI.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government